| CDKN2B-AS1 |
|
CDKN2B antisense RNA 1
|
|
|
0.491 |
0.769 |
| LINC02571 |
|
long intergenic non-protein coding RNA 2571
|
|
|
0.743 |
0.500 |
| ZNRD1ASP |
|
zinc ribbon domain containing 1 antisense, pseudogene
|
|
|
0.691 |
0.538 |
| MIR4435-2HG |
|
MIR4435-2 host gene
|
|
|
0.604 |
0.692 |
| PCAT1 |
|
prostate cancer associated transcript 1
|
|
|
0.575 |
0.615 |
| RTEL1-TNFRSF6B |
|
RTEL1-TNFRSF6B readthrough (NMD candidate)
|
|
|
0.682 |
0.385 |
| PTCSC2 |
|
papillary thyroid carcinoma susceptibility candidate 2
|
|
|
0.751 |
0.231 |
| DRAIC |
|
downregulated RNA in cancer, inhibitor of cell invasion and migration
|
|
|
0.736 |
0.423 |
| CASC15 |
|
cancer susceptibility 15
|
|
|
0.603 |
0.577 |
| CASC8 |
|
cancer susceptibility 8
|
|
|
0.670 |
0.462 |
| CASC16 |
|
cancer susceptibility 16
|
|
|
0.780 |
0.308 |
| CCAT2 |
|
colon cancer associated transcript 2
|
|
|
0.621 |
0.615 |
| CASC19 |
|
cancer susceptibility 19
|
|
|
0.769 |
0.423 |
| AFG3L1P |
|
AFG3 like matrix AAA peptidase subunit 1, pseudogene
|
|
|
0.931 |
0.115 |
| CASC11 |
|
cancer susceptibility 11
|
|
|
0.641 |
0.577 |
| PRNCR1 |
|
prostate cancer associated non-coding RNA 1
|
|
|
0.722 |
0.385 |
| LINC01416 |
|
long intergenic non-protein coding RNA 1416
|
|
|
0.890 |
0.154 |
| LINC02143 |
|
long intergenic non-protein coding RNA 2143
|
|
|
0.890 |
0.154 |
| LINC01496 |
|
long intergenic non-protein coding RNA 1496
|
|
|
0.890 |
0.154 |
| EMBP1 |
|
embigin pseudogene 1
|
|
|
0.839 |
0.269 |
| NBAT1 |
|
neuroblastoma associated transcript 1
|
|
|
0.650 |
0.423 |
| ETF1P1 |
|
eukaryotic translation termination factor 1 pseudogene 1
|
|
|
1.000 |
0.115 |
| HYKK |
A2RU49
|
hydroxylysine kinase
|
|
7.3E-06 |
0.769 |
0.346 |
| MAP1LC3B2 |
A6NCE7
|
microtubule associated protein 1 light chain 3 beta 2
|
|
1.3E-02 |
0.931 |
0.192 |
| COLCA2 |
A8K830
|
colorectal cancer associated 2
|
|
0.75 |
0.769 |
0.154 |